![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Publisher: Bentham Science Publishers
E-ISSN: 1875-5933|2|2|131-136
ISSN: 1568-010X
Source: Current Drug Targets. Inflammation & Allergy, Vol.2, Iss.2, 2003-06, pp. : 131-136
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Novel therapy for Crohn’s disease targeting IL-6 signalling
By Ito Hiroaki
Expert Opinion on Therapeutic Targets, Vol. 8, Iss. 4, 2004-08 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Current Drug Targets. Inflammation & Allergy, Vol. 2, Iss. 2, 2003-06 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
IL-10: treatment option for Crohn's disease?
Inpharma, Vol. 1, Iss. 1273, 2001-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Vercirnon for the treatment of Crohn's disease
By Arseneau Kristen O Cominelli Fabio
Expert Opinion on Investigational Drugs, Vol. 22, Iss. 7, 2013-11 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Adalimumab a charming treatment for Crohn's disease
Inpharma, Vol. 1, Iss. 1544, 2006-01 ,pp. :